| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10050536 | HBV | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
| TVIS10049990 | HBV | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
| TVIS30008799 | HIV | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
| TVIS20012134 | HPV | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
| TVIS20024726 | HPV | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
| TVIS44004386 | HTLV-1 | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
| TVIS44038861 | HTLV-1 | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
| TVIS44038892 | HTLV-1 | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
| TVIS44038891 | HTLV-1 | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
| TVIS44045060 | HTLV-1 | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | DHFR |
|---|---|
| DrugBank ID | DB00642 |
| Drug Name | Pemetrexed |
| Target ID | BE0000330 |
| UniProt ID | P00374 |
| Regulation Type | inhibitor |
| PubMed IDs | 11524555; 11763166; 11841783; 11848474; 12023793; 11752352; 11252887; 11531245; 11742712; 14596699; 15795320; 12571811 |
| Citations | Hanauske AR, Chen V, Paoletti P, Niyikiza C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist. 2001;6(4):363-73.@@Norman P: Pemetrexed disodium (Eli Lilly). Curr Opin Investig Drugs. 2001 Nov;2(11):1611-22.@@Mauritz R, Peters GJ, Priest DG, Assaraf YG, Drori S, Kathmann I, Noordhuis P, Bunni MA, Rosowsky A, Schornagel JH, Pinedo HM, Jansen G: Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem Pharmacol. 2002 Jan 15;63(2):105-15.@@Schultz RM, Dempsey JA: Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells. Anticancer Res. 2001 Sep-Oct;21(5):3209-14.@@Adjei AA: Pemetrexed in the treatment of selected solid tumors. Semin Oncol. 2002 Apr;29(2 Suppl 5):50-3.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Adjei AA: Gemcitabine and Pemetrexed disodium in treating breast cancer. Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):34-7.@@Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M: Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 2001 Sep 1;85(5):649-55.@@Adjei AA: Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. Lung Cancer. 2001 Dec;34 Suppl 4:S103-5.@@Molina JR, Adjei AA: The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy. Clin Lung Cancer. 2003 Jul;5(1):21-7.@@Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol. 2005 Jul;68(1):110-8. Epub 2005 Mar 28.@@Kindler HL: Pemetrexed in pancreatic cancer. Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53. |
| Groups | Approved; Investigational |
| Direct Classification | Glutamic acid and derivatives |
| SMILES | NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1 |
| Pathways | |
| PharmGKB | PA10810 |
| ChEMBL | CHEMBL225072 |
